Show
Sort by
-
- Journal Article
- A1
- open access
Comparative effectiveness of autologous hematopoietic stem cell transplant vs fingolimod, natalizumab, and ocrelizumab in highly active relapsing-remitting multiple sclerosis
-
- Journal Article
- A1
- open access
Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation : a retrospective analysis from the Lymphoma Working Party of the EBMT
-
- Journal Article
- A1
- open access
AUGMENT : a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
-
AUGMENT : a phase III randomized study of lenalidomide plus rituximab (R-2) vs rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
- Journal Article
- A1
- open access
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
-
Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma
-
Ibrutinib vs temsirolimus: results from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma (MCL)